We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 23, 2019

Oral Care Evaluation to Prevent Oral Mucositis in ER+ MBC Patients Treated With Everolimus

The Oncologist


Additional Info

Disclosure statements are available on the authors' profiles:

The Oncologist
Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated With Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial
Oncologist 2019 Oct 08;[EPub Ahead of Print], N Niikura, K Nakatukasa, T Amemiya, KI Watanabe, H Hata, Y Kikawa, N Taniike, T Yamanaka, S Mitsunaga, K Nakagami, M Adachi, N Kondo, Y Shibuya, N Hayashi, M Naito, K Kashiwabara, T Yamashita, M Umeda, H Mukai, Y Ota

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading